Table 3.
Medication at Discharge and Clinical Outcomes
| TIMI Risk Score for Secondary Prevention | P Value | |||
|---|---|---|---|---|
| Low Risk (n=2421) | Intermediate Risk (n=1788) | High Risk (n=2618) | ||
| Medication at discharge | ||||
| Aspirin | 2349 (97.7) | 1708 (96.1) | 2367 (92.7) | <0.001 |
| P2Y12 inhibitor | 2116 (88.0) | 1518 (85.7) | 2048 (80.3) | <0.001 |
| Statin | 2271 (95.0) | 1693 (96.1) | 2324 (92.1) | <0.001 |
| ACEI/ARB | 1712 (70.8) | 1450 (81.0) | 1980 (75.7) | <0.001 |
| β‐Blockers | 1861 (78.8) | 1433 (81.8) | 2040 (81.0) | 0.041 |
| Anticoagulants | 68 (2.8) | 79 (4.5) | 236 (9.2) | <0.001 |
| Outcomes | ||||
| 30‐d rehospitalization | 369 (17.1) | 307 (19.3) | 430 (19.5) | 0.077 |
| 30‐d recurrent MI | 32 (1.3) | 24 (1.3) | 53 (2.0) | 0.084 |
| 30‐d MACE | 173 (7.2) | 147 (8.2) | 395 (15.1) | <0.001 |
| 30‐d mortality | 26 (1.1) | 35 (2.0) | 191 (7.3) | <0.001 |
| 30‐d MI or UAP | 96 (4.0) | 76 (4.2) | 176 (6.7) | <0.001 |
| 30‐d CVA | 3 (0.1) | 8 (0.4) | 16 (0.8) | 0.52 |
| 30‐d stent thrombosis | 17 (0.7) | 14 (0.8) | 23 (0.9) | 0.77 |
| 30‐d urgent revascularization | 90 (3.7) | 63 (3.5) | 107 (4.1) | 0.60 |
| 1‐y mortalitya | 45 (1.9) | 81 (4.6) | 409 (15.8) | <0.001 |
Values are presented as n (%). Anticoagulants include warfarin, enoxaparin, dabigatran, apixaban, rivaroxaban, and fondaparinux. MACE includes death, UAP, MI, CVA, stent thrombosis, and urgent revascularization. P2Y12 inhibitors include clopidogrel, ticagrelor, and prasugrel. ACEI indicates angiotensin‐converting enzyme inhibitor; ARB, angiotensin receptor blocker; CVA, cerebrovascular accident; MI, myocardial infarction; MACE, major adverse cardiac events; TIMI, Thrombolysis in Myocardial Infarction; UAP, unstable angina pectoris.
a
Percentages are Kaplan–Meier rates.